No Data
No Data
PTC Therapeutics Is Maintained at Overweight by JP Morgan
PTC Therapeutics Analyst Ratings
Express News | PTC Therapeutics Inc : JP Morgan Cuts Target Price to $75 From $78
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $60
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics: Strategic Growth and Market Expansion Justify Buy Rating Amid Regulatory Challenges